Results
eNauka >
Rezultati >
The Expiry of Humira(R) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
| Naziv: | The Expiry of Humira(R) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures | Autori  : | Moorkens, Evelien; ...; Novakovic, Tanja; ...; (broj, koautora 43) | Godina: | 2021 | Publikacija: | FRONTIERS IN PHARMACOLOGY | ISSN: | 1663-9812 Frontiers in Pharmacology Pretraži identifikator |
Tip rezultata: | Naučni članak | Kolacija: | vol. 11 | DOI: | 10.3389/fphar.2020.591134 | WoS-ID: | 000612144800001 | Scopus-ID: | 2-s2.0-85099607758 | PMID: | 33519450 | PMCID: | PMC7839249 | URI: | https://enauka.gov.rs/handle/123456789/797016 | Projekat: | KULeuvenKU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) |
Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.